Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamidronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 12/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamidronic Acid SCHEMBL4260287 | 0.98 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL506809 | 0.98 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570526 | 0.91 | FDPS (0.78) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570525 | 0.82 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL2641229 | 0.80 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL11037738 | 0.80 | FDPS (0.61) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL328770 | 0.79 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL11106361 | 0.77 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL18361 | 0.77 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL204535 | 0.77 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18750 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-20260027088-A1 | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | UNIV EMORY (US) | 2026-01-29 | — | — | US | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250232860-A1 | SMART DOSING FOR CANCER THERAPY | OPTIMDOSING LLC (US) | 2025-07-17 | — | — | US | claimed |
| EP-1210063-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | Lipocine, Inc. (US) | 2002-06-05 | — | — | EP | claimed |
| US-20010039952-A1 | ULTRASOUND ENHANCED CHEMOTHERAPY | WALTER A. HACKER, PH. D | 2001-11-15 | — | — | US | claimed |
| WO-2001082949-A2 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| US-6308714-B1 | Ultrasound enhanced chemotherapy | CORAJE, INC. | 2001-10-30 | — | — | US | claimed |
| US-6309663-B1 | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents | LIPOCINE INC. | 2001-10-30 | — | — | US | claimed |
| US-6248363-B1 | Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents | LIPOCINE, INC. | 2001-06-19 | — | — | US | claimed |
| WO-2001037808-A1 | SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS | LIPOCINE, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001032101-A1 | BONE HEMOSTASIS METHOD AND MATERIALS | CHILDREN'S HOSPITAL LOS ANGELES (US) | 2001-05-10 | — | — | WO | claimed |
| WO-2001028555-A1 | EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS | LIPOCINE, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2001012155-A1 | COMPOSITIONS AND METHODS FOR ENHANCED ABSORPTION OF HYDROPHILIC THERAPEUTIC AGENTS | LIPOCINE, INC. (US) | 2001-02-22 | — | — | WO | claimed |